ArticleFrontiers in oncology2025

Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumab.

Henrik Horndalsveen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.